SMAD2 and chronic kidney disease: Targeting CKD with 3WJ-Kapt/anti-miR-34a in this study was associated with rapid downregulation of the expression level of miR-34a, reaching a completely normal level after the 1st week of treatment followed by complete normalization of the renal expression of TGF-β, SMAD2/3, klotho, WNT1, and β-catenin.